Interestingly, compared to CMS/PDS, pan-cancer immune subtyping (IS)34 did not differ significantly based on SARIFA-status or TAF (each p > 0.5), with most CRC cases in general being of “wound healing” or “interferon-gamma dominant” subtype (Supplementary Fig. 1b), potentially indicating that site-specific transcriptomic CRC classifiers (CMS & PDS) may better correlate with prognostically and biologically relevant histologic features (SARIFA/TAF). This evidence concerns the gene IFNG and cancer.